Cell Therapy Market Size to Grow At 22.67% CAGR Till 2033

The global cell therapy market size was valued at USD 4.85 billion in 2023 and is projected to surpass around USD 37.42 billion by 2033, registering a CAGR of 22.67% over the forecast period of 2024 to 2033 according to Nova One Advisor.

Key Takeaways:

• North America accounted for the largest revenue share of 60.0% in 2023.
• Asia Pacific is estimated to register a significant CAGR during the forecast period
• Autologous therapy segment dominated the market with a share of 92.0% in the year 2023.
• The oncology segment dominated the overall market with the largest revenue share 78% in 2023.

Get Sample Copy of Report@ https://www.novaoneadvisor.com/report/sample/7874

Cell Therapy Market Size in U.S. 2024 to 2033

The U.S. cell therapy market size was valued at USD 2.88 billion in 2023 and is anticipated to reach around USD 19.67 billion by 2033, growing at a CAGR of 21.18 % from 2024 to 2033.

North America accounted for the largest revenue share of 60.0% in 2023. This is attributed to the collaborative research initiatives by research institutes and the pharmaceutical giants. There are emerging advancements in the region through numerous collaborations. For instance, in June 2023, Immatics entered into a collaboration with Bristol Myers Squibb to develop Gamma Delta Allogeneic Cell Therapy Programs. The availability of funds from government organizations significantly contributes to market growth in the U.S. For instance, in January 2023, Cellino Biotech announced that it raised around USD 80 million through a Series A financing round from 8VC, Felicis Ventures, and other investors. The company plans to use these funds to expand access to stem cell-derived therapies to develop the first independent human cell foundry by 2025.

Asia Pacific is estimated to register a significant CAGR during the forecast period due to increased demand for cell therapy in the region. Certain factors, such as increasing awareness about novel therapies, growing investments, and expected favorable policies by governments, are estimated to accelerate market growth during the forecast period. For instance, in June 2023, Tessa Therapeutics Ltd. raised USD 126 million through rounds of series funding to catalyze the development of next-generation cancer therapy. Similarly, the South Korean market is expected to exhibit lucrative growth due to various strategic initiatives undertaken by local players and international companies. For instance, in August 2023, Panacell Biotech announced that it would be using Natural Killer (NK) cells, brown Adipose-Derived Stem Cells (ADSC), and exosomes for treating COVID-19 infection.

Ask Here for Customization@ https://www.novaoneadvisor.com/report/customization/7874

Cell Therapy Market Growth Factors

The market for cell therapy is constantly growing to include new cell types, which presents significant opportunities for companies to strengthen their market positions. As a result, during the past few years, there has been a dramatic increase in the number of companies engaged in developing cell therapies.

The rise in funding for cell therapy clinical studies, the adoption of useful guidelines for cell therapy manufacturing, and the success of products are some of the major factors influencing the growth in the number of companies in the market. The development of cell banking facilities and the ensuing growth in cell manufacturing, storage, and characterization have enhanced the market’s ability to handle large volumes on a global scale. Furthermore, several companies are offering cell therapy characterization research and analysis services which is boosting the growth of cell-based therapeutics manufacturing. This has directly contributed to the market’s increased revenue generation over the previous few years.

The increase in the number of clinical trials can be attributed to the presence of private and government funding agencies that are constantly providing approvals to support projects across different stages of clinical trials. The majority of late-stage projects in Europe are receiving funds through EU grants. For instance, in July 2022, Achilles Therapeutics declared that it had been awarded a USD 4.2 million Horizon Europe, the EU’s key funding initiative for research and innovation. This funding was awarded to advance personalized therapy manufacturing.

The rise of personalized medicine has led to an increase in clinical studies. Cellular therapies, especially those involving genetically modified cells, offer the potential for customized treatments that target the unique genetic makeup of individual patients. This personalized analysis enhances treatment effectiveness and minimizes adverse effects, marking a paradigm shift in the way healthcare is delivered.

Stem cell therapy is also increasingly gaining attention due to its applications in therapeutics for autoimmune and metabolic disorders. It plays an essential role in developing immunity in an individual to fight against various metabolic disorders. For instance, in May 2022, Sernova and Evotec entered into a collaboration for development of cell therapy to be used for the treatment of insulin-dependent diabetes using induced pluripotent stem cells (iPSC)-based therapeutics.

In addition, automation in adult stem cells & cord blood processing and storage are the key technologies expected to positively influence growth of the adult & cord blood cells market. Furthermore, key entities in the market are involved in collaborations to reprogram newborn stem cells from umbilical cord blood as well as tissue into induced pluripotent stem cells (IPSCs). These developments are expected to drive growth of market over the forecast period.

Cell Therapy Market Top Trends 2024

• Commercialization of CAR-T Therapies: Chimeric Antigen Receptor T-cell (CAR-T) therapies continue to dominate the market, with more products gaining approval and entering commercialization. These innovative treatments offer promising outcomes for patients with certain types of leukaemia and lymphoma.
• Expansion Beyond Oncology: While oncology remains a primary focus, cell therapy is expanding into other therapeutic areas such as autoimmune diseases, cardiovascular disorders, and neurological conditions. This diversification of applications is opening up new market opportunities and driving further research and development efforts.
• Development of Off-the-Shelf Therapies: Efforts to develop allogeneic or “off-the-shelf” cell therapies are intensifying, aiming to overcome the logistical challenges associated with personalized autologous therapies. These off-the-shelf products have the potential to streamline manufacturing processes and improve accessibility for patients.
• Advancements in Gene Editing Technologies: Gene editing technologies like CRISPR-Cas9 are revolutionizing cell therapy by enabling precise modifications to cell genomes. These advancements enhance the therapeutic potential of cell-based treatments and pave the way for the development of more sophisticated therapies with improved efficacy and safety profiles.
• Focus on Scalability and Manufacturing Efficiency: With increasing demand for cell therapies, there is a growing emphasis on scalability and manufacturing efficiency. Innovations in bioprocessing technologies, automation, and quality control are aimed at optimizing manufacturing processes to meet the market demand and reduce production costs.
• Emergence of Next-Generation Cell Therapies: Next-generation cell therapies, such as engineered cell therapies, stem cell-based therapies, and regenerative medicine approaches, are gaining traction. These advanced therapies offer novel mechanisms of action and have the potential to address unmet medical needs across various disease areas.
• Personalized Medicine: Tailoring cell therapies to individual patients’ genetic makeup and specific medical needs is gaining traction. This approach maximizes efficacy while minimizing adverse reactions.
• Gene Editing Technologies: Advancements in gene editing tools like CRISPR-Cas9 are revolutionizing cell therapy. These technologies enable precise modifications to cell genomes, enhancing therapeutic outcomes.
• Allogeneic Therapies: Allogeneic cell therapies, derived from healthy donor cells, are gaining prominence due to their potential for off-the-shelf availability and cost-effectiveness compared to autologous therapies.
• Combination Therapies: Combining cell therapies with other treatment modalities like immunotherapy or small molecules enhances their efficacy and expands their applicability across various diseases.

Immediate Delivery Available | Buy This Premium Research

https://www.novaoneadvisor.com/report/checkout/7874

Segments Insights:

Therapy Type Insights

Autologous therapy segment dominated the market with a share of 92.0% in the year 2023. The growth in the segment is attributed to the high adoption of numerous CAR-T therapies owing to its favorable outcomes for treatment of various types of cancers and genetic disorders. The FDA has approved some of such therapies and their wider adoption is currently under progress. For instance, in February 2023, the U.S. FDA accorded its approval to the drug called ciltacabtagene autoleucel (Carvykti) for adult subjects with multiple myeloma that is irresponsive to the refractory therapeutics or that has relapsed after therapeutics.

Allogeneic cell therapy segment is estimated to register substantial growth in the market from 2024 to 2033. The growth can be attributed to its high adoption for designing novel therapeutic regimes. There are 542 active allogenic CAR-T agents in the global pipeline, with many of them yielding favorable outcomes. For instance, Adaptimmune Ltd. collaborates with Genentech to focus on utility of allogeneic therapies derived from iPSCs to create T-cells with higher proliferation capacity than the mature T-cells.

Therapeutic Area Insights

The oncology segment dominated the overall market with the largest revenue share 78% in 2023. CAR T-cells targeting CD19 are reported to provide high rates of complete and long-lasting remissions for patients with acute lymphocytic leukemia (ALL). Furthermore, increasing FDA approval for novel therapies is expected to create growth opportunities for the market. For instance, in October 2021, the U.S. FDA approved the use of the brexucabtagene autoleucel (Tecartus), a CAR T therapy for individuals with B-cell precursor ALL who have not responded to prior treatment (refractory) or whose condition has returned after treatment. With this approval, brexucabtagene became the first CAR T treatment for adults with ALL.

The musculoskeletal disorders segment is anticipated to witness significant market expansion in the forthcoming years. Considerable research is being conducted on technologies aimed at enabling the regeneration or restoration of impaired musculoskeletal tissues. Researchers across diverse groups are analyzing clinically applicable cell types used in therapies to address musculoskeletal tissue degeneration. They are also exploring the direct application of engineered or native skeletal progenitor cells to stimulate tissue repair and revitalize musculoskeletal tissues. These factors are expected to drive the segment growth.

Recent Developments

• In October 2023, Aurion Biotech began a phase 1/2 clinical trial of cell therapy for corneal edema in the U.S.
• In October 2023, Nkarta, Inc. announced the FDA’s approval of an IND application to investigate NKX019, its allogeneic, CD19-directed CAR NK cell therapy candidate, to cure lupus nephritis.
• In June 2023, Vertex Pharmaceuticals Incorporated and Lonza revealed a joint venture to facilitate the manufacturing of Vertex’s portfolios of investigational stem cell therapies. These therapies are designed to aid individuals with Type 1 Diabetes (T1D), with a specific focus on the VX-880 and VX-264 programs currently undergoing clinical trials.
• In May 2023, Johnson & Johnson signed a global collaboration & licensing agreement with Cellular Biomedicine Group to develop next-generation CAR-T therapies.
• In March 2023, Adaptimmune Therapeutics plc. and TCR2 Therapeutics announced a strategic alliance to form a world-class cell therapy organization for solid tumors.
• In May 2023, the Bristol-Myers Squibb Company received European Commission (EC) approval for Breyanzi for treatment of refractory or relapsed large B-cell lymphoma in adult patients. This approval would improve company’s position in European market
• In January 2020, the Novartis AG announced that Kymriah would be publicly funded to treat eligible adult patients with relapsed or refractory DLBCL in Australia.

Some of the prominent players in the Cell therapy market include:

• Novartis AG
• Gilead Sciences, Inc.
• Bristol-Myers Squibb Company
• Johnson & Johnson Services, Inc
• JCR Pharmaceuticals Co., Ltd.
• JW Therapeutics
• Atara Biotherapeutics
• Anterogen Co., Ltd.
• MEDIPOST
• S. BIOMEDICS
• Aurion Biotech
• Holostem Terapie Avanzate S.r.l
• Nkarta, Inc.

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the global cell therapy market.

• Therapy Type
  • Allogeneic Therapies
    • Stem Cell Therapies
      • Hematopoietic Stem Cell Therapies
      • Mesenchymal Stem Cell Therapies
    • Non-Stem Cell Therapies
      • Keratinocytes & Fibroblast-based Therapies
      • Others
  • Autologous Therapies
    • Stem Cell Therapies
      • BM, Blood, & Umbilical Cord-derived Stem Cells
      • Adipose Derived Cells
      • Others
    • Non-Stem Cell Therapies
      • T-Cell Therapies
        • CAR T Cell Therapy
        • T Cell Receptor (TCR)-based
      • Others
• Therapeutic Area Outlook
  • Oncology
  • Cardiovascular Disease (CVD)
  • Musculoskeletal Disorders
  • Dermatology
  • Others
• Regional Outlook
  • North America
  • Europe
  • Asia Pacific
  • Rest of the World

Immediate Delivery Available | Buy This Premium Research

https://www.novaoneadvisor.com/report/checkout/7874

Call: USA: +1 650 460 3308 | IND: +91 87933 22019 |Europe: +44 2080772818

Email: sales@novaoneadvisor.com

Web: https://www.novaoneadvisor.com/